CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

PartnershipIn-Body CAR-T TechnologyPositive
AI Analysis

Summary

Tempest Therapeutics has gained an option to license in-body CAR-T technology from Senlang, expanding its cell therapy pipeline through a strategic partnership.

Importance:6/10
Sentiment:
0.60
licensingpartnershipCAR-Tcell therapy
Related Companies

Read the original article

Published by yahoo_finance on September 15, 2026 9:45 PM

Read Original